Last updated: 22 July 2019 at 11:55pm EST

Peter Bluford Net Worth

The estimated Net Worth of Peter Bluford is at least $240 mil dollars as of 4 October 2004. Peter Bluford owns over 500 units of Sangamo Therapeutics Inc stock worth over $114,064 and over the last 21 years Peter sold SGMO stock worth over $125,935.

Peter Bluford SGMO stock SEC Form 4 insiders trading

Peter has made over 42 trades of the Sangamo Therapeutics Inc stock since 2003, according to the Form 4 filled with the SEC. Most recently Peter sold 500 units of SGMO stock worth $2,500 on 4 October 2004.

The largest trade Peter's ever made was selling 1,000 units of Sangamo Therapeutics Inc stock on 14 January 2004 worth over $7,500. On average, Peter trades about 507 units every 8 days since 2003. As of 4 October 2004 Peter still owns at least 135,791 units of Sangamo Therapeutics Inc stock.

You can see the complete history of Peter Bluford stock trades at the bottom of the page.

What's Peter Bluford's mailing address?

Peter's mailing address filed with the SEC is C/O SANGAMO BIOSCIENCES IN STE.A-100, POINT RICHMOND TECH CENTER 501 CANA BLVD, RICHMOND, CA, 94804.

Insiders trading at Sangamo Therapeutics Inc

Over the last 24 years, insiders at Sangamo Therapeutics Inc have traded over $87,969,621 worth of Sangamo Therapeutics Inc stock and bought 3,434,008 units worth $48,483,268 . The most active insiders traders include Capital Management, L.P.Ra ..., Le Roy C Kopp, eInc.Biogen Ma Inc. Biogen. On average, Sangamo Therapeutics Inc executives and independent directors trade stock every 21 days with the average trade being worth of $40,671. The most recent stock trade was executed by Inc.Biogen Ma Inc. Biogen on 26 September 2023, trading 6,000,000 units of SGMO stock currently worth $3,000,000.

What does Sangamo Therapeutics Inc do?

for sangamo therapeutics, science is a means to develop new medicines with the potential to transform the lives of patients living with serious genetic diseases. our scientists are leaders in the discovery, research and development of technologies enabling gene-based therapeutic development. currently we are conducting clinical trials, including the first ever in vivo human genome editing studies. to learn more about sangamo, visit the our website at www.sangamo.com.

Complete history of Peter Bluford stock trades at Sangamo Therapeutics Inc

Acionista maioritário	Trans. Transação	Preço total
Peter Bluford V.P. e Corporate Development	Venda	$2,500 4 Oct 2004
Peter Bluford V.P. e Corporate Development	Venda	$2,650 27 Sep 2004
Peter Bluford V.P. e Corporate Development	Venda	$2,500 20 Sep 2004
Peter Bluford V.P. e Corporate Development	Venda	$2,575 15 Sep 2004
Peter Bluford V.P. e Corporate Development	Venda	$2,780 12 Jul 2004
Peter Bluford V.P. e Corporate Development	Venda	$2,750 6 Jul 2004
Peter Bluford V.P. e Corporate Development	Venda	$2,820 28 Jun 2004
Peter Bluford V.P. e Corporate Development	Venda	$2,900 21 Jun 2004
Peter Bluford V.P. e Corporate Development	Venda	$2,705 14 Jun 2004
Peter Bluford V.P. e Corporate Development	Venda	$3,085 7 Jun 2004
Peter Bluford V.P. e Corporate Development	Venda	$2,975 1 Jun 2004
Peter Bluford V.P. e Corporate Development	Venda	$2,825 24 May 2004
Peter Bluford V.P. e Corporate Development	Venda	$2,975 17 May 2004
Peter Bluford V.P. e Corporate Development	Venda	$3,060 10 May 2004
Peter Bluford V.P. e Corporate Development	Venda	$3,205 3 May 2004
Peter Bluford V.P. e Corporate Development	Venda	$3,270 26 Apr 2004
Peter Bluford V.P. e Corporate Development	Venda	$2,935 19 Apr 2004
Peter Bluford V.P. e Corporate Development	Venda	$3,090 12 Apr 2004
Peter Bluford V.P. e Corporate Development	Venda	$3,255 5 Apr 2004
Peter Bluford V.P. e Corporate Development	Venda	$2,835 29 Mar 2004
Peter Bluford V.P. e Corporate Development	Venda	$2,855 22 Mar 2004
Peter Bluford V.P. e Corporate Development	Venda	$3,105 15 Mar 2004
Peter Bluford V.P. e Corporate Development	Venda	$3,285 8 Mar 2004
Peter Bluford V.P. e Corporate Development	Venda	$2,765 1 Mar 2004
Peter Bluford V.P. e Corporate Development	Venda	$2,955 23 Feb 2004
Peter Bluford V.P. e Corporate Development	Venda	$3,130 17 Feb 2004
Peter Bluford V.P. e Corporate Development	Venda	$2,780 9 Feb 2004
Peter Bluford V.P. e Corporate Development	Venda	$2,960 2 Feb 2004
Peter Bluford V.P. e Corporate Development	Venda	$3,370 26 Jan 2004
Peter Bluford V.P. e Corporate Development	Venda	$3,585 20 Jan 2004
Peter Bluford V.P. e Corporate Development	Venda	$7,500 14 Jan 2004
Peter Bluford V.P. e Corporate Development	Venda	$3,075 12 Jan 2004
Peter Bluford V.P. e Corporate Development	Venda	$2,670 5 Jan 2004
Peter Bluford V.P. e Corporate Development	Venda	$2,550 29 Dec 2003
Peter Bluford V.P. e Corporate Development	Venda	$2,500 22 Dec 2003
Peter Bluford V.P. e Corporate Development	Venda	$2,500 15 Dec 2003
Peter Bluford V.P. e Corporate Development	Venda	$1,500 9 Dec 2003
Peter Bluford V.P. e Corporate Development	Venda	$2,500 5 Dec 2003
Peter Bluford V.P. e Corporate Development	Venda	$2,525 10 Nov 2003
Peter Bluford V.P. e Corporate Development	Venda	$2,500 3 Nov 2003
Peter Bluford V.P. e Corporate Development	Venda	$2,545 28 Oct 2003
Peter Bluford V.P. e Corporate Development	Venda	$5,090 16 Oct 2003

Sangamo Therapeutics Inc executives and stock owners

Sangamo Therapeutics Inc executives and other stock owners filed with the SEC include:

Alexander Macrae,
President, Chief Executive Officer, Director
Sung Lee,
Chief Financial Officer, Executive Vice President
Gary Loeb,
Executive Vice President, Chief Compliance Officer, General Counsel, Secretary
Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D.,
CEO, Pres & Director
R. Andrew Ramelmeier,
Executive Vice President - Technical Operations
Dr. R. Andrew Ramelmeier Ph.D.,
Exec. VP of Technical Operations
D. Mark McClung,
Exec. VP & COO
James Meyers,
Independent Director
H. Stewart Parker,
Independent Director
Joseph Zakrzewski,
Independent Director
Robert Carey,
Independent Director
Saira Ramasastry,
Independent Director
Karen Smith,
Independent Director
McDavid Stilwell,
IR Contact Officer
John Markels,
Independent Director
Kenneth Hillan,
Director
Prathyusha Duraibabu,
Vice President - Finance
D. Mark McClung,
Executive Vice President, Chief Business Officer
Scott B. Willoughby,
Sr. VP, Gen. Counsel & Corp. Sec.
Prathyusha Duraibabu CPA, M.B.A.,
Sr. VP, CFO & Principal Accounting Officer
Dr. Jason D. Fontenot Ph.D.,
Sr. VP & Chief Scientific Officer
Prathyusha Duraibabu,
VP of Fin., Principal Accounting Officer & Principal Financial Officer
Dr. Duncan McKay,
Sr. VP & GM of Europe
Heather Erickson,
Chief of Staff
Dr. Nathalie Dubois-Stringfellow,
Sr. VP of Product Devel. & Management
Whitney Jones,
Sr. VP & Chief People Officer
Aron Feingold,
Head of Corp. Communications & Investor Relations Officer
Dr. Jason Fontenot Ph.D.,
Sr. VP & Chief Scientific Officer
Stephen George Dilly,
Director
Paul B Cleveland,
Director
Henry Ward Wolff,
Director
Steven J Mento,
Director
William R Ringo,
Director
Geoffrey Nichol,
Executive Vice President, R&D
Curt A. Iii Herberts,
Sr.VP & Chief Business Officer
Dale G Ando,
VP, Therapeutic Dev. & CMO
Edward R. Conner,
Sr. VP & Chief Medical Officer
Thomas G Wiggans,
Director
William G Gerber,
Director
Roger Jeffs,
Director
Heather D Turner,
EVP, General Counsel & Sec.
Robert J. Schott,
SVP, Head of Development
Stephane Boissel,
EVP, Corp. Strategy
Kathy Yi,
EVP & Chief Financial Officer
Margaret Liu,
Director
Michael C Wood,
Director
Greg Zante,
Sr Dir., Finance and Admin
Le Roy C Kopp,
10% owner
Edward O Ii Lanphier,
President and CEO
Jon E M Jacoby,
Director
Casey C Case,
Vice President, Research
Peter Bluford,
V.P., Corporate Development
William J Rutter,
Director
John William Larson,
Director
Philip D Gregory,
Vice President, Research
Capital Management, L.P.Ra ...,
David G Ichikawa,
Senior VP, Bus. Dev.
Jason D. Fontenot,
SVP, Chief Scientific Officer
Scott B. Willoughby,
SVP, GEN. COUNSEL & SECRETARY
Inc.Biogen Ma Inc. Biogen,
Sandy Macrae,
PRESIDENT, CEO AND DIRECTOR
Nathalie Dubois Stringfellow,
SVP-CHIEF DEVELOPMENT OFFICER
Amy Pooler,
VP, HEAD OF RESEARCH
Courtney Beers,
Margaret A Horn,